Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
2.38 (USD) • At close September 8, 2025
 Overzicht | Financiële gegevens
 | Bedrijfsnaam | Iovance Biotherapeutics, Inc. | 
| Symbool | IOVA | 
| Munteenheid | USD | 
| Prijs | 2.38 | 
| Beurswaarde    |  861,212,520 | 
| Dividendpercentage    |  0% | 
| 52-weken bereik | 1.64 - 12.51 | 
| Industrie | Biotechnology | 
| Sector | Healthcare | 
| CEO | Dr. Frederick G. Vogt Esq., J.D., Ph.D. | 
| Website | https://www.iovance.com | 
An error occurred while fetching data.
Over Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; 
 Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)









